New Drug Pricing Agreements: President Trump announced nine agreements with major pharmaceutical companies to lower prescription drug prices for Americans, aligning U.S. prices with the most-favored-nation (MFN) pricing used in other developed countries.
Significant Cost Reductions: The agreements will lead to substantial price drops for various medications, such as Amgen's Repatha from $573 to $239 and Gilead's Hepatitis C treatment Epclusa from $24,920 to $2,425, benefiting patients directly.
Investment in U.S. Manufacturing: The participating pharmaceutical companies have committed to invest at least $150 billion in U.S. manufacturing, enhancing national health security and reducing dependence on foreign supply chains.
Emergency Preparedness Contributions: Several companies will donate active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to ensure the U.S. has adequate supplies of critical medicines during emergencies.
Wall Street analysts forecast GILD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GILD is 137.88 USD with a low forecast of 105.00 USD and a high forecast of 154.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
Wall Street analysts forecast GILD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GILD is 137.88 USD with a low forecast of 105.00 USD and a high forecast of 154.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 131.140
Low
105.00
Averages
137.88
High
154.00
Current: 131.140
Low
105.00
Averages
137.88
High
154.00
BofA
Buy
maintain
$144 -> $154
2026-01-09
Reason
BofA
Price Target
$144 -> $154
AI Analysis
2026-01-09
maintain
Buy
Reason
BofA raised the firm's price target on Gilead to $154 from $144 and keeps a Buy rating on the shares. The firm, which switched its valuation method, says the company's "steady" HIV franchise growth remains core to its Buy thesis as it sees upside from recent and upcoming launches.
UBS
Michael Yee
Neutral -> Buy
upgrade
$112 -> $145
2026-01-07
Reason
UBS
Michael Yee
Price Target
$112 -> $145
2026-01-07
upgrade
Neutral -> Buy
Reason
UBS analyst Michael Yee upgraded Gilead to Buy from Neutral with a price target of $145, up from $112, after assuming coverage of the name. The firm cites its expectations for "strong" HIV pre-exposure prophylaxis sales from Yeztugo for the upgrade. This should drive revenue and earnings upside as well as increasing confidence in Gilead's outer-year growth, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GILD
Unlock Now
Citi
Geoff Meacham
Buy
maintain
$135 -> $140
2026-01-07
Reason
Citi
Geoff Meacham
Price Target
$135 -> $140
2026-01-07
maintain
Buy
Reason
Citi analyst Geoff Meacham raised the firm's price target on Gilead to $140 from $135 and keeps a Buy rating on the shares.
Morgan Stanley
Overweight
maintain
$147 -> $151
2025-12-12
Reason
Morgan Stanley
Price Target
$147 -> $151
2025-12-12
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Gilead to $151 from $147 and keeps an Overweight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
